Core Viewpoint - Morgan Stanley has a more positive outlook on Kelun-Botai Biopharmaceutical (06990), raising its revenue forecast for 2025 to 2033 by 1% to 10% and increasing the target price from HKD 499 to HKD 545, citing multiple catalysts expected in 2026 [1] Group 1 - The company recently announced positive data from the Phase III clinical trial of SKB264 (sac-TMT) in mainland China, marking the first successful Phase III trial for sac-TMT in first-line treatment of non-small cell lung cancer (NSCLC) [1] - This trial is also the first globally to demonstrate that the ADC+PD-1 combination therapy is superior to PD-1 monotherapy in first-line treatment of NSCLC [1] - Based on the trial results, the company plans to submit a supplemental new drug application (sNDA) for sac-TMT targeting the relevant indications in China [1]

Core Viewpoint - Kolon Biotech Inc. (06990) shares rose nearly 5% in early trading, reflecting positive market sentiment following the announcement of successful Phase III clinical trial data for SKB264 (sac-TMT) [1] Group 1: Clinical Trial Results - The recent Phase III clinical trial results for sac-TMT indicate a significant advancement, marking the first successful Phase III trial for sac-TMT in first-line treatment of non-small cell lung cancer (NSCLC) [1] - This trial is also noted as the first globally to demonstrate that the ADC+PD-1 combination therapy is superior to PD-1 monotherapy in first-line NSCLC treatment [1] Group 2: Financial Projections and Analyst Ratings - Following the positive trial results, the company plans to submit a supplemental new drug application (sNDA) for sac-TMT targeting relevant indications in China [1] - JPMorgan has raised its revenue forecasts for the company by 1% to 10% for the years 2025 to 2033, and increased the target price from 499 HKD to 545 HKD [1] - The firm continues to view the company positively, maintaining its "overweight" rating and identifying it as a preferred stock in the Chinese biopharmaceutical sector, anticipating multiple catalysts in 2026 [1]